Annexon Biosciences Lands $44,000,000 Series B Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9a44c46e-ee14-47a6-8704-7bd56efcd484 - Date
6/23/2016 - Company Name
Annexon Biosciences - Mailing Address
280 Utah Avenue South San Francisco, CA 94080 USA - Company Description
Annexon is a California-based healthcare company engaged in the R&D of novel disease-modifying drugs for neurodegenerative disorders. - Website
http://www.annexonbio.com - Transaction Type
Venture Equity - Transaction Amount
$44,000,000 - Transaction Round
Series B - Proceeds Purposes
This significant investment in our robust and risk-balanced pipeline further validates Annexon’s novel and elegant scientific approach. Moreover, the funding enables us to enhance and accelerate our biomarker-rich clinical development program in support of new and much-needed therapies for patients with serious neurodegenerative disorders. - M&A Terms
- Venture Investor
New Enterprise Associates - Venture Investor
Correlation Ventures - Venture Investor
Novartis Venture Fund - Venture Investor
Clarus Ventures - Venture Investor
Satter Investment Management
